iZafe Group’s Quarterly Report Q4, October–December 2025
16 februari, 08:30
16 februari, 08:30
iZafe Group AB (publ.) today, February 16, publishes its report for the fourth quarter.
Financial Performance in Summary
Significant events during the quarter
Significant events after the end of the quarter
FORECAST
In this report, we present a forecast chart illustrating our expected growth in both ARR and active Dosell units in the coming years. The forecast is based on our current markets and key metrics and shows a clear path toward continued strong growth in recurring revenues as more units are activated.
At the beginning of 2026, our ARR amounted to approximately SEK 10 million, representing an increase of 488 percent compared with the previous year. During 2026, this growth is expected to accelerate further, with ARR forecasted to reach SEK 22.5 million by year end, an increase of 125 percent. We will follow up on this forecast quarterly to provide you as shareholders with a clear picture of our actual development and how we are progressing toward our financial targets.
2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
ARR (MSEK) | 0.3 | 1.7 | 10 | 22.5 | 42.3 | 63.9 | 85.5 |
Growth of Dosells | 0 % | 326 % | 352 % | 125 % | 69 % | 41 % | 29% |
Comments from the CEO
2025 has been the year in which iZafe Group firmly established its scalable business model. The fourth quarter confirms this in the numbers. Net sales for the quarter amounted to 2,435 TSEK and consisted entirely of recurring license revenues. We have thereby transitioned from a period in which hardware deliveries dominated revenue to a business now fully driven by subscription-based income.
We enter 2026 with approximately 10 MSEK in annual recurring revenue, in line with our previously communicated forecast for the fourth quarter. This marks an important milestone in the Company’s development and demonstrates that our strategy is delivering results.
Today, we are a company fully focused on building annual recurring revenue (ARR). First, we deploy our units with customers. Thereafter, a stable ARR base develops, generating margins and long-term predictable earnings.
A growing customer base with built-in scalability
Today, we have more than 30 municipalities in Sweden and 29 active customers in the Netherlands. Sweden and the Netherlands are our two prioritized core markets and represent significant growth potential going forward. Our established customer base provides a stable and scalable platform for continued expansion.
Nordic and international expansion
During the quarter, we further strengthened our Nordic presence through new partnerships in Norway, Iceland and Finland. These are important steps that confirm the scalability of our model beyond our original markets.
In the Netherlands, we have fully integrated the operations following the acquisition of our former distributor. This provides improved control, a higher revenue share per unit and a clearer growth platform. In 2026, we plan to continue investing in the Dutch organization to accelerate development in the Dutch market, which is the largest in Europe in terms of the use of dose-dispensed medication pouches.
We see clear and growing interest across several European countries for secure and connected solutions for medication management in the home. Our position continues to strengthen through both partnerships and direct market presence.
Product development driving competitiveness
Dosell continues to evolve in line with our growth, which is essential to meet increasing customer requirements and strengthen our market position. After the end of the reporting period, we launched a modular external Display for Dosell as well as a new remote care system with a web interface and mobile application. This makes Dosell more flexible and adaptable to different user needs. With this launch, Dosell together with the remote care system has achieved MDR Class I compliance, strengthening our competitiveness in public procurements and larger contracts.
Outlook and the road ahead
The forecast previously communicated remains unchanged. With an entry level of approximately 10 MSEK in ARR, we enter 2026 with a stable and growing base.
During 2026, we will focus both on expanding our customer base and on increasing the penetration rate among existing customers. While we have won several new customers, the real leverage arises when we increase the number of active units within existing municipalities and customer organizations. As Dosell demonstrates clear value in daily operations, we see usage gradually expand, where customer satisfaction drives both higher penetration and new business opportunities through references and procurements.
An important factor during 2026 is the ongoing ADDA procurement process. The outcome has not yet been communicated, but we see significant strategic value in Dosell potentially becoming part of the framework agreement. Such an outcome would further strengthen our position in the Swedish market and facilitate adoption for a large number of municipalities. However, our current forecast does not include this agreement.
We are operating in a strong phase of development. Our business model is established. Our recurring revenues are growing. Our customer base continues to expand. Our product platform is broader, more flexible and better positioned for continued growth.
We have laid the foundation. In 2026, we continue to scale.
I would like to extend my sincere thanks to our employees, partners and shareholders for your continued trust. The journey continues, and we enter 2026 with focus, structure and a clear ambition for growth.
Anders Segerström
Chief Executive Officer, iZafe Group
Contacts
Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm
E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group
About iZafe Group AB (publ.)
iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.
The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.
The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.
iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company’s Certified Adviser is DNB Carnegie Investment Bank AB. Further information is available at www.izafegroup.com
This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-16 08:30 CET.
Image Attachments
Attachments
16 februari, 08:30
iZafe Group AB (publ.) today, February 16, publishes its report for the fourth quarter.
Financial Performance in Summary
Significant events during the quarter
Significant events after the end of the quarter
FORECAST
In this report, we present a forecast chart illustrating our expected growth in both ARR and active Dosell units in the coming years. The forecast is based on our current markets and key metrics and shows a clear path toward continued strong growth in recurring revenues as more units are activated.
At the beginning of 2026, our ARR amounted to approximately SEK 10 million, representing an increase of 488 percent compared with the previous year. During 2026, this growth is expected to accelerate further, with ARR forecasted to reach SEK 22.5 million by year end, an increase of 125 percent. We will follow up on this forecast quarterly to provide you as shareholders with a clear picture of our actual development and how we are progressing toward our financial targets.
2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
ARR (MSEK) | 0.3 | 1.7 | 10 | 22.5 | 42.3 | 63.9 | 85.5 |
Growth of Dosells | 0 % | 326 % | 352 % | 125 % | 69 % | 41 % | 29% |
Comments from the CEO
2025 has been the year in which iZafe Group firmly established its scalable business model. The fourth quarter confirms this in the numbers. Net sales for the quarter amounted to 2,435 TSEK and consisted entirely of recurring license revenues. We have thereby transitioned from a period in which hardware deliveries dominated revenue to a business now fully driven by subscription-based income.
We enter 2026 with approximately 10 MSEK in annual recurring revenue, in line with our previously communicated forecast for the fourth quarter. This marks an important milestone in the Company’s development and demonstrates that our strategy is delivering results.
Today, we are a company fully focused on building annual recurring revenue (ARR). First, we deploy our units with customers. Thereafter, a stable ARR base develops, generating margins and long-term predictable earnings.
A growing customer base with built-in scalability
Today, we have more than 30 municipalities in Sweden and 29 active customers in the Netherlands. Sweden and the Netherlands are our two prioritized core markets and represent significant growth potential going forward. Our established customer base provides a stable and scalable platform for continued expansion.
Nordic and international expansion
During the quarter, we further strengthened our Nordic presence through new partnerships in Norway, Iceland and Finland. These are important steps that confirm the scalability of our model beyond our original markets.
In the Netherlands, we have fully integrated the operations following the acquisition of our former distributor. This provides improved control, a higher revenue share per unit and a clearer growth platform. In 2026, we plan to continue investing in the Dutch organization to accelerate development in the Dutch market, which is the largest in Europe in terms of the use of dose-dispensed medication pouches.
We see clear and growing interest across several European countries for secure and connected solutions for medication management in the home. Our position continues to strengthen through both partnerships and direct market presence.
Product development driving competitiveness
Dosell continues to evolve in line with our growth, which is essential to meet increasing customer requirements and strengthen our market position. After the end of the reporting period, we launched a modular external Display for Dosell as well as a new remote care system with a web interface and mobile application. This makes Dosell more flexible and adaptable to different user needs. With this launch, Dosell together with the remote care system has achieved MDR Class I compliance, strengthening our competitiveness in public procurements and larger contracts.
Outlook and the road ahead
The forecast previously communicated remains unchanged. With an entry level of approximately 10 MSEK in ARR, we enter 2026 with a stable and growing base.
During 2026, we will focus both on expanding our customer base and on increasing the penetration rate among existing customers. While we have won several new customers, the real leverage arises when we increase the number of active units within existing municipalities and customer organizations. As Dosell demonstrates clear value in daily operations, we see usage gradually expand, where customer satisfaction drives both higher penetration and new business opportunities through references and procurements.
An important factor during 2026 is the ongoing ADDA procurement process. The outcome has not yet been communicated, but we see significant strategic value in Dosell potentially becoming part of the framework agreement. Such an outcome would further strengthen our position in the Swedish market and facilitate adoption for a large number of municipalities. However, our current forecast does not include this agreement.
We are operating in a strong phase of development. Our business model is established. Our recurring revenues are growing. Our customer base continues to expand. Our product platform is broader, more flexible and better positioned for continued growth.
We have laid the foundation. In 2026, we continue to scale.
I would like to extend my sincere thanks to our employees, partners and shareholders for your continued trust. The journey continues, and we enter 2026 with focus, structure and a clear ambition for growth.
Anders Segerström
Chief Executive Officer, iZafe Group
Contacts
Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm
E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group
About iZafe Group AB (publ.)
iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.
The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.
The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.
iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company’s Certified Adviser is DNB Carnegie Investment Bank AB. Further information is available at www.izafegroup.com
This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-16 08:30 CET.
Image Attachments
Attachments
Blankningar
Analys
Internationellt
Nvidia
Blankningar
Analys
Internationellt
Nvidia
1 DAG %
Senast


BioGaia
Igår, 07:00
BioGaia: Gräver guld i USA
Matpriser
28 februari, 08:00
Så mycket dyrare har mellomyset blivit – chokladen rusar
Christer Gardell
27 februari, 15:33
Gardell om Klarna: "Ett misstag att notera i USA"
HAKI Safety
27 februari, 14:56
Haki Safety: Intressant aktie – men osäkra utsikter
Amazon.com
27 februari, 14:49
Amazon backar i förhandeln medan Netflix rusar
OMX Stockholm 30
1 DAG %
Senast
3 222,75